---
title: Comparisons of Two Low-density Lipoprotein Apheresis Systems in Patients With Homozygous Familial Hypercholesterolemia
nct_id: NCT02286596
overall_status: COMPLETED
sponsor: Laval University
study_type: OBSERVATIONAL
primary_condition: Homozygous Familial Hypercholesterolemia
countries: Canada
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02286596.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02286596"
ct_last_update_post_date: 2016-03-08
last_seen_at: "2026-05-12T06:13:53.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Comparisons of Two Low-density Lipoprotein Apheresis Systems in Patients With Homozygous Familial Hypercholesterolemia

**NCT ID:** [NCT02286596](https://clinicaltrials.gov/study/NCT02286596)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 9
- **Lead Sponsor:** Laval University
- **Conditions:** Homozygous Familial Hypercholesterolemia
- **Start Date:** 2013-04
- **Completion Date:** 2014-12
- **CT.gov Last Update:** 2016-03-08

## Brief Summary

Homozygous familial hypercholesterolemia (HoFH) is characterized by a six- to eight-fold raise in plasma LDL-cholesterol (LDL-C) concentrations and atherosclerotic coronary artery disease usually occur before the age of 20 if untreated. Lipid apheresis (LA) has been proved to be a reliable method to decrease LDL-C concentrations and therefore decrease cardiovascular disease risk in HoFH. The objective of this crossover study was to compare efficacy of LA performed with heparin-induced extracorporeal LDL precipitation to dextran sulfate adsorption on the reduction of lipids, inflammatory markers, adhesion molecules and LDL particles size in a cohort of HoFH subjects.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 60 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Aged between 18-65 years
* Subjects with homozygous familial hypercholesterolemia:
* Carrier of a mutation in the LDL receptor gene

Exclusion Criteria:

* Subjects with a previous history of cardiovascular disease
* Subjects with Type 2 diabetes
* Were pregnant or nursing;
* Subjects with a history of cancer
* Subjects with acute liver disease, hepatic dysfunction, or persistent elevations of serum transaminases
* Subjects with a secondary hyperlipidemia due to any cause
* History of alcohol or drug abuse within the past 2 years
* hormonal treatment
* Subjects who are in a situation or have any condition that, in the opinion of the investigator, may interfere with optimal participation in the study
```

## Arms

- **heparin-induced extracorporeal LDL precipitation** — Lipid apheresis treatment for 3 hours
- **dextran sulfate adsorption** — Lipid apheresis treatment for 3 hours

## Interventions

- **heparin-induced extracorporeal LDL precipitation** (DEVICE) — Lipid apheresis for 3 hours
- **dextran sulfate adsorption** (DEVICE) — Lipid apheresis for 3 hours

## Primary Outcomes

- **Change in plasma lipid levels between the two lipid apheresis treatment** _(time frame: At the end of the two lipid apheresis (Week 0 and 2))_

## Secondary Outcomes

- **Change in plasma adhesion molecule levels between the two lipid apheresis treatment** _(time frame: At the end of the two lipid apheresis (Week 0 and 2))_
- **Change in plasma inflammatory marker levels between the two lipid apheresis treatment** _(time frame: At the end of the two lipid apheresis (Week 0 and 2))_
- **Change in LDL particle size between the two lipid apheresis treatment** _(time frame: At the end of the two lipid apheresis (Week 0 and 2))_

## Locations (1)

- Institute of Nutrition and Functional Foods (INAF), Québec, Quebec, Canada

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.institute of nutrition and functional foods (inaf)|québec|quebec|canada` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02286596.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02286596*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*